Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy in Intractable Cryptogenic Epilepsy
NCT02695797Phase 4Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Sep 2015
- Primary completion
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of immune globulin and prednisolone in epilepsy (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Percent seizure reduction at 3 months. Status: unknown.
02
Drugs
immune globulinprednisolone
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02695797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02695797.